ABBVIE
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2800
- Registration Number
- NCT06345339
- Locations
- ๐บ๐ธ
St. Louis University /ID# 262375, Saint Louis, Missouri, United States
๐บ๐ธDiabetes and Endocrinology Specialists /ID# 259068, Chesterfield, Missouri, United States
๐บ๐ธOmega Clinical Research /ID# 260162, Metairie, Louisiana, United States
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
- Conditions
- Moderate Plaque Psoriasis
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 393
- Registration Number
- NCT06333860
- Locations
- ๐บ๐ธ
Allcutis Research /ID# 263024, Portsmouth, New Hampshire, United States
๐บ๐ธTotal Skin and Beauty Dermatology Center /ID# 263011, Birmingham, Alabama, United States
๐บ๐ธAdvanced Research Associates - Glendale /ID# 263621, Glendale, Arizona, United States
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT06332534
- Locations
- ๐บ๐ธ
Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford, Connecticut, United States
๐บ๐ธUCSF Benioff Children's Hospital - Oakland /ID# 262217, Oakland, California, United States
๐บ๐ธOSF St. Francis Medical Center /ID# 262192, Peoria, Illinois, United States
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 140
- Registration Number
- NCT06318273
- Locations
- ๐บ๐ธ
City of Hope /ID# 262059, Duarte, California, United States
๐บ๐ธUniv California, San Francisco /ID# 261715, San Francisco, California, United States
๐บ๐ธYale University School of Medicine /ID# 262234, New Haven, Connecticut, United States
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 161
- Registration Number
- NCT06308198
- Locations
- ๐จ๐ณ
Beijing Hospital /ID# 256084, Beijing, Beijing, China
๐ฏ๐ตTokyo Center Clinic /ID# 267380, Chuo-ku, Tokyo, Japan
๐จ๐ณDermatology Hospital of Southern Medical University /ID# 256172, Guangzhou, Guangdong, China
Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 11
- Registration Number
- NCT06300580
- Locations
- ๐ฌ๐ง
Parexel Early Phase Clinical Unit /ID# 264286, Harrow, United Kingdom
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT06291220
- Locations
- ๐ฉ๐ช
Universitaetsklinikum Ulm /ID# 263148, Ulm, Baden-Wuerttemberg, Germany
๐บ๐ธCity of Hope /ID# 253904, Duarte, California, United States
๐บ๐ธCity of Hope Orange County Lennar Foundation Cancer Center /ID# 267158, Irvine, California, United States
A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT06278766
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit Inc /ID# 262684, Madison, Wisconsin, United States
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT06257875
- Locations
- ๐ฎ๐ฑ
Tel Aviv Sourasky Medical Center /ID# 258528, Tel Aviv, Tel-Aviv, Israel
๐บ๐ธGastro SB /ID# 258331, Chula Vista, California, United States
๐บ๐ธSouthern California Res. Ctr. /ID# 258391, Coronado, California, United States
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder
- Conditions
- Bipolar I Disorder
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 170
- Registration Number
- NCT06256367
- Locations
- ๐บ๐ธ
UC Davis /ID# 259723, Sacramento, California, United States
๐บ๐ธUt Southwestern Medical Center /Parkland Health and Hospital System /Id# 260001, Dallas, Texas, United States
๐บ๐ธUniversity of Alabama at Birmingham - Main /ID# 260000, Birmingham, Alabama, United States